



*cancers*



an Open Access Journal by MDPI

## Latest Basic, Translational and Clinical Advancements in HER2-Positive Breast Cancer

Guest Editors:

**Dr. Serenella Pupa**

Molecular Targeting Unit,  
Department of Research,  
Fondazione IRCCS Istituto  
Nazionale dei Tumori,  
AmadeoLab, Via Amadeo 42,  
20133 Milan, Italy

**Dr. Elda Tagliabue**

Head of Molecular Targeting Unit,  
Department of Research,  
AmadeoLab, Fondazione IRCCS  
Istituto Nazionale dei Tumori, Via  
Amadeo 42, 20133 Milan, Italy

Deadline for manuscript  
submissions:

**closed (1 October 2022)**

### Message from the Guest Editors

Breast cancer is one of the most common malignancies worldwide. Between 15% and 20% of breast cancers harbor HER2 overexpression and/or amplification, which is associated with an aggressive course of disease. While results overwhelmingly demonstrate the clinical benefit of HER2-targeted therapy, a considerable number of patients do not benefit. Thus, advancements in an improved understanding of HER2-positive breast cancer biology, immunology, metabolism, genomics, and epigenetics, as well as the selection of more suited tailored treatments and predictive criteria of response to therapies, are still mandatory goals to be achieved. Indeed, HER2-driven cancer recurrence continues to be a real and significant clinical concern. This Special Issue will bring together expert researchers and physicians focusing on the latest key findings in the field of HER2-driven basic and translational research. It will also cover innovations in detection tools and treatment options of HER2-positive breast cancer.



[mdpi.com/si/51414](https://mdpi.com/si/51414)

# Special Issue



**cancers**



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

## Contact Us

*Cancers* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
X@Cancers\_MDPI